{"id":"NCT00532155","sponsor":"Sanofi","briefTitle":"A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer","officialTitle":"A Multinational, Randomized, Double-Blind Study Comparing Aflibercept Versus Placebo in Patients Treated With Second-Line Docetaxel After Failure of One Platinum Based Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2011-01","completion":"2011-10","firstPosted":"2007-09-20","resultsPosted":"2013-01-01","lastUpdate":"2025-09-10"},"enrollment":913,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma","Non Small Cell Lung"],"interventions":[{"type":"DRUG","name":"Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Docetaxel (Taxotere®)","otherNames":[]},{"type":"DRUG","name":"Dexamethasone (pre- and post-medication for docetaxel)","otherNames":[]}],"arms":[{"label":"Aflibercept/Docetaxel","type":"EXPERIMENTAL"},{"label":"Placebo/Docetaxel","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of the study was to demonstrate overall survival improvement for aflibercept + docetaxel compared to docetaxel + placebo as second line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC).\n\nThe secondary objectives were to compare other efficacy parameters, to assess the overall safety of the two treatment arms, to assess the pharmacokinetics of intravenous (IV) aflibercept in this participant population and to determine immunogenicity of IV aflibercept in all participants.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Baseline to the date when 687 deaths occurred (26 January 2011)","effectByArm":[{"arm":"Placebo/Docetaxel","deltaMin":10.41,"sd":null},{"arm":"Aflibercept/Docetaxel","deltaMin":10.05,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.8985"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":32,"countries":["United States","Argentina","Australia","Austria","Brazil","Bulgaria","Canada","Chile","China","Czechia","Estonia","Finland","France","Germany","Greece","Hong Kong","Hungary","India","Italy","Malaysia","Netherlands","Poland","Portugal","Romania","Russia","Singapore","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["22965962"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":159,"n":453},"commonTop":["Alopecia","Fatigue","Stomatitis","Diarrhoea","Decreased appetite"]}}